Outcome of the Board Meeting held on August 21, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and 1.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board of Pharmaids Pharmaceuticals approved the audited standalone and consolidated financial statements for FY ended March 31, 2025, along with the Board's Report, Management Discussion & Analysis, and Corporate Governance Report. Notably, there were no adverse observations or qualifications from the statutory or secretarial auditors that required explanation. The board approved the notice for the 36th Annual General Meeting to be held via video conferencing and appointed CS Kashinath Sahu as both the scrutinizer for e-voting and the new Secretarial Auditor for a five-year term (FY 2025-26 to FY 2029-30). Additionally, the continuation of Independent Director Mr. P N Vijay was approved, subject to shareholder approval at the upcoming AGM.
Routine corporate housekeeping announcement with no material financial surprises. The clean audit opinion (no auditor qualifications) is mildly positive for shareholder confidence, while the five-year secretarial auditor appointment signals governance stability.